Denali Therapeutics Inc. (DNLI) Tops Q1 EPS by 2c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q1 EPS of ($0.68), $0.02 better than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Denali Therapeutics to sell priority review voucher for $195M
• Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million